DEA Reviews Continuus Pharmaceuticals' Application for Bulk Drug Manufacturing
Published Date: 8/21/2025
Notice
Summary
Continuus Pharmaceuticals wants to become an official big-time maker of certain controlled drugs. This means they’ll be allowed to produce these substances in large amounts, which could impact medicine supply and safety. If approved, this change will help keep important medicines available while following strict rules.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13145 — Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)
Almac Clinical Services Incorp. (ACSI) wants to become an official importer of certain controlled substances, including psilocybin and oxycodone. This affects drug manufacturers and others in the industry who can comment or request a hearing by July 30, 2026. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.
2026-13144 — Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Catalent Pharma Solutions wants to become an official importer of some powerful controlled substances like LSD and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by July 30, 2026. This move could impact companies involved in these substances and the government’s control over them.
2026-12654 — Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
Previous / Next Documents
Previous: 2025-16006 — Importer of Controlled Substances Application: Vici Health Sciences, LLC
Vici Health Sciences, LLC wants to become an official importer of certain controlled substances. This means they’ll be allowed to bring in specific drugs that need special handling and rules. If approved, this could affect companies and regulators keeping track of these substances, with no immediate cost changes announced.
Next: 2025-16009 — Agency Information Collection Activities; Comment Request on Form 4506, 4506T-EZ and 4506T-EZ (SP)
The IRS wants your thoughts on updating Forms 4506, 4506T-EZ, and 4506T-EZ (SP), which people use to request tax transcripts. If you’ve ever needed these forms, this affects you! The IRS aims to make the forms easier and quicker to use, so expect smoother paperwork soon. They’re asking for comments before making changes, so now’s the time to speak up!